0000939767-17-000039.txt : 20170317 0000939767-17-000039.hdr.sgml : 20170317 20170317195238 ACCESSION NUMBER: 0000939767-17-000039 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170315 FILED AS OF DATE: 20170317 DATE AS OF CHANGE: 20170317 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EXELIXIS, INC. CENTRAL INDEX KEY: 0000939767 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 043257395 STATE OF INCORPORATION: DE FISCAL YEAR END: 0102 BUSINESS ADDRESS: STREET 1: 210 E. GRAND AVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6508377000 MAIL ADDRESS: STREET 1: 210 E. GRAND AVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: EXELIXIS INC DATE OF NAME CHANGE: 20000207 FORMER COMPANY: FORMER CONFORMED NAME: EXELIXIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20000106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WILLSEY LANCE CENTRAL INDEX KEY: 0001202106 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30235 FILM NUMBER: 17699830 MAIL ADDRESS: STREET 1: C/O EXELIXIS INC STREET 2: 170 HARBOR WAY CITY: SAN FRANCISCO STATE: CA ZIP: 94083 4 1 wf-form4_148979474359671.xml FORM 4 X0306 4 2017-03-15 0 0000939767 EXELIXIS, INC. EXEL 0001202106 WILLSEY LANCE C/O EXELIXIS, INC. 210 E. GRAND AVE. SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Common Stock 2017-03-15 4 M 0 10000 10.53 A 578273 D Common Stock 2017-03-15 4 S 0 10000 22.86 D 568273 D Option (right to buy) 10.53 2017-03-15 4 M 0 10000 0 D 2007-05-02 2017-05-01 Common Stock 10000.0 0 D Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.85 to $22.89. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. The option, representing the right to purchase a total of 10,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 2, 2007. /s/ Jeffrey J. Hessekiel, Attorney in Fact 2017-03-17